|
1
|
Pagano L, Caira M, Candoni A, et al: The
epidemiology of fungal infections in patients with hematologic
malignancies: the SEIFEM-2004 study. Haematologica. 91:1068–1075.
2006.PubMed/NCBI
|
|
2
|
Böhme A, Ruhnke M, Buchheidt D, et al:
Treatment of invasive fungal infections in cancer patients -
recommendations of the Infectious Diseases Working Party (AGIHO) of
the German Society of Hematology and Oncology (DGHO). Ann Hematol.
88:97–110. 2009.
|
|
3
|
Girmenia C, Pagano L, Corvatta L, et al:
The epidemiology of fusariosis in patients with haematological
diseases. Gimema Infection Programme. Br J Haematol. 111:272–276.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boutati EI and Anaissie EJ:
Fusarium, a significant emerging pathogen in patients with
hematologic malignancy: ten years’ experience at a cancer center
and implications for management. Blood. 90:999–1008.
1997.PubMed/NCBI
|
|
5
|
Nucci M and Anaissie E: Fusarium
infections in immunocompromised patients. Clin Microbiol Rev.
20:695–704. 2007. View Article : Google Scholar
|
|
6
|
Liang DC, Yang CP, Lin DT, et al:
Long-term results of Taiwan Pediatric Oncology Group studies 1997
and 2002 for childhood acute lymphoblastic leukemia. Leukemia.
24:397–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fleischhack G, Hasan C, Graf N, Mann G and
Bode U: IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an
effective remission-induction therapy for poor-prognosis AML of
childhood prior to allogeneic or autologous bone marrow
transplantation: experiences of a phase II trial. Br J Haematol.
102:647–655. 1998. View Article : Google Scholar
|
|
8
|
Nucci M, Anaissie EJ, Queiroz-Telles F, et
al: Outcome predictors of 84 patients with hematologic malignancies
and Fusarium infection. Cancer. 98:315–319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dignani MC and Anaissie EJ: Human
fusariosis. Clin Microbiol Infect. 10(Suppl 1): 67–75. 2004.
View Article : Google Scholar
|
|
10
|
Chaoui D, Legrand O, Roche N, et al:
Incidence and prognostic value of respiratory events in acute
leukemia. Leukemia. 18:670–675. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grigis A, Farina C, Symoens F, Nolard N
and Goglio A: Nosocomial pseudo-outbreak of Fusarium
verticillioides associated with sterile plastic containers. Infect
Control Hosp Epidemiol. 21:50–52. 2000.
|
|
12
|
Rüping MJ, Vehreschild JJ and Cornely OA:
Antifungal treatment strategies in high risk patients. Mycoses.
51(Suppl 2): 46–51. 2008.
|
|
13
|
Tortorano AM, Esposto MC, Prigitano A,
Grancini A, Ossi C, Cavanna C and Cascio GL: Cross-reactivity of
Fusarium spp. in the Aspergillus Galactomannan
enzyme-linked immunosorbent assay. J Clin Microbiol. 50:1051–1053.
2012.
|
|
14
|
Cetkovsky P, Kouba M, Markova M, et al:
Combination of voriconazole and anidulafungin as primary therapy in
hematologic patients. Biol Blood Marrow Transplant. 16:S2642010.
View Article : Google Scholar
|
|
15
|
Rojas R, Molina JR, Jarque I, et al:
Outcome of antifungal combination therapy for invasive mold
infections in hematological patients is independent for chosen
combination. Mediterr J Hematol Infect Dis. 4:e20120112012.
View Article : Google Scholar
|
|
16
|
Liu JY, Chen WT, Ko BS, et al: Combination
antifungal therapy for disseminated fusariosis in immunocompromised
patients: a case report and literature review. Med Mycol.
49:872–878. 2011.PubMed/NCBI
|
